Abstract:Cryptosporidium infection is highly prevalent among immunocompromised patients with Acquired Immunodeficiency Syndrome, cancer, primary immunodeficiency, and organ transplant recipients. Comprehensive knowledge about Cryptosporidium infection provides the means for efficient diagnosis, treatment, and prevention. Therefore, with the objective of providing an in‐depth analysis of Cryptosporidiosis in immunocompromised patients, this review presents a comprehensive understating of the prevalence, risk factors, pathophysiology of Cryptosporidium infection, clinical presentation in the immunocompromised, the immune response of the host, diagnostic methods performed in laboratory settings, possible treatments, and prevention methods, which can be used for further studies. Peer‐reviewed, published, original articles on cryptosporidiosis in immunocompromised patients were searched using specific key‐words on PubMed, ResearchGate, Google Scholar, and ScienceDirect databases. Articles which were accessible to the date of 18 th of August 2023, were included in this comprehensive review. We analyzed reports on Cryptosporidium in immunocompromised patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), cancer, primary immunodeficiency, and organ transplant recipients. 134 Articles describing epidemiology, related risk factors, clinical presentation, diagnosis, and possible treatments in the light of pathogenesis, pathophysiology, and virulence factors of Cryptosporidium and immunology of the host are summarized in this study. Effective treatments to be administered, importance, and ways of prevention were identified. Cryptosporidium infection was found to be highly prevalent among immunocompromised in Asia, Africa, Europe, and North America. The immunity of the host and the decrease in CD4 + T‐cell count were found to the main factors which decide the susceptibility and the severity of infection. Drugs that activate host immunity and suppress Cryptosporidium growth, along with supportive therapy, is an effective treatment. But prevention is the most effective strategy for immunocompromised patients; thus, a better understanding about the disease would lead to effective prevention.

CryptosporidiumSpecies

The Genome of Cryptosporidium Hominis

Global population genomics of two subspecies of Cryptosporidium hominis during 500 years of evolution

First Survey of Cryptosporidium, Giardia and Enterocytozoon in Diarrhoeic Children from Wuhan, China

Widespread occurrence of Cryptosporidium infections in patients with HIV/AIDS: Epidemiology, clinical feature, diagnosis, and therapy

Complete Genome Sequence of the Apicomplexan, Cryptosporidium Parvum

Animal Propagation And Genomic Survey Of A Genotype 1 Isolate Of Cryptosporidium Parvum

Life cycle progression and sexual development of the apicomplexan parasite Cryptosporidium parvum

Characterization of a Species-Specific Insulinase-Like Protease in Cryptosporidium Parvum.

Cryptosporidiosis in developing countries.

Cryptosporidiosis Modulates the Gut Microbiome and Metabolism in a Murine Infection Model

Cryptosporidiosis in a Zoonotic Gastrointestinal Disorder Perspective

Transcriptional control of the Cryptosporidium life cycle

Cryptosporidiosis in Developing Countries

Genetic Recombination And Cryptosporidium Hominis Virulent Subtype Iba10g2

Mendelian segregation and high recombination rates facilitate genetic analyses in Cryptosporidium parvum

Subtyping Cryptosporidium xiaoi, a Common Pathogen in Sheep and Goats

Emerging therapeutic avenues against Cryptosporidium: A comprehensive review

CDPKs of Cryptosporidium parvum—stage-specific expression in vitro

Targeted CRISPR Screens Reveal Genes Essential for Cryptosporidium Survival in the Host Intestine

Treatment of Cryptosporidium: What We Know, Gaps, and the Way Forward